Overview

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

Status:
COMPLETED
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca